2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy

Gilead Highlights Oncology Ambitions In Q4

Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.

Overcoming challenges and crisis . Mixed media — Gilead touted its oncology pipeline in its fourth quarter/full year 2021 earnings • Source: Shutterstock

Gilead Sciences, Inc. started off the year stating at the J.P. Morgan Healthcare Conference that oncology will account for one-third of its revenues by 2030. The firm’s 2021 sales demonstrate that it is largely dependent on infectious disease, but management used the 1 February earnings call to highlight some near-term catalysts in oncology that will help the firm with its diversification efforts.

“Our 2022 plans include a significant increase in clinical development studies across our novel oncology portfolio,” CEO Daniel O’Day told...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

28 May 2025

• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

26 May 2025

• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.